PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.

Juanita Lopez,Manuel SelviMiralles,Malaka Ameratunga,Anna Minchom,Javier Pascual,Udai Banerji,Hannah Bye,Florence I. Raynaud,Karen E Swales,Jason Malia,Michael Hubank,Isaac Garcia-Murillas,Mona Parmar,Sarah Emily Ward,Laura Finneran,Emma Hall,Alison Joanne Turner,Johann S. de Bono,Timothy A. Yap,Nicholas C. Turner

PIPA: A phase Ib study of selective ß-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) in patients (pts) with advanced solid cancers—Safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the doublet combination.

2019

3087Background: Oncogenic hyperactivation of the PI3K pathway is common in multiple cancers, with preclinical data showing that CDK4/6 inhibitors sensitise PIK3CA mutant cancers to PI3K inhibitors....

Keywords:

Palbociclib
PI3K/AKT/mTOR pathway
Phosphatidylinositol
Pharmacodynamics
Gene isoform
Pathology
Kinase
Pharmacology
Pharmacokinetics
Medicine
Tolerability
Cancer research
Hyperactivation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations